Analysis of putative N-linked glycosylation sites and variable region of envelope HIV-1 CRF07_BC recombinant in intravenous drug users in Xinjiang Autonomous Region, China

AIDS Research and Human Retroviruses

Volumn 24, Issue 3, 2008, Pages 521-527

  Liu, Shengya ^a,b,c   Xing, Hui ^a   He, Xiang ^a   Xin, Ruolei ^a   Zhang, Yuanzhi ^d   Zhu, Jiahong ^c   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Medical Laboratory of Shenzhen International Travel Healthcare Center   (China)

^c Wuhan Institute of Biological Products   (China)

^d The Center for Disease Control and Prevention of Xinjiang Uygur Autonomous Region   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABUSE; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS ENVELOPE; VIRUS GENE; VIRUS TRANSMISSION;

CHINA; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MOLECULAR SEQUENCE DATA; SELECTION (GENETICS); SEQUENCE ANALYSIS, DNA; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 41449107853     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0254     Document Type: Article

References (31)

1. Eicher AD, Crofts N, Benjamin S, Deutschmann P, and Rodger AJ: A certain fate: Spread of HIV among young injecting drug users in Manipur, north-east India. AIDS Care 2000;12:497-504.
2. Aceijas C, Stimson GV, Hickman M, and Rhodes T: Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 2004;18:2295-2303.
3. Zheng X, Tian C, Choi KH, et al.: Injecting drug use and HIV infection in southwest China. AIDS 1994;8:1141-1147.
4. Piyasirisilp S, McCutchan FE, Carr JK, et al.: A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol 2000;74:11286-11295.
5. McClutchan FE, Carr JK, Murphy D, et al.: Precise mapping of recombination breakpoints suggests a common parent of two BC recombinant HIV type 1 strains circulating in China. AIDS Res Hum Retroviruses 2002;18:1135-1140.
6. Yang R, Xia X, Kusagawa S, Zhang C, Ben K, and Takebe Y: Ongoing generation of multiple forms of HIV-1 intersubtype recombinants in the Yunnan Province of China. AIDS 2002;16:1401-1407.
7. Shao Y, Pang P, et al.: The evolution of subtype C HIV-1 and its recombinant forms among IDUs in China. XIII International AIDS Congress 167, Durban, South Africa, July 9-14, 2000.
8. Xing H, Liang H, et al.: The evolution and rapid spread of B/C recombinant HIV-1 strains in western China. XIV International AIDS Congress, TuOrC1191, Barcelona, Spain, July 7-12, 2002.
9. Albert J, Abrahamsson B, Nagy K, et al.: Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990;4:107-112.
10. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
11. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, and Simmonds P: Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993;67:3345-3356.
12. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al.: Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004;303:2019-2022.
13. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
14. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-74.
15. Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, and Paxton WA: Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 2004;78:524-530.
16. Saitou N and Nei M: The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-425.
17. Thompson JD, Higgins DG, and Gibson TJ: CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
18. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
19. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
20. Chohan B, Lang D, Sagar M, et al.: Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005;79:6528-6531.
21. Herring BL, Tsui R, Peddada L, Busch M, and Delwart EL: Wide range of quasispecies diversity during primary hepatitis C virus infection. J Virol 2005;79:4340-4346.
22. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-659.
23. Wyatt R, Kwong PD, Desjardins E, et al.: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-711.
24. McCaffrey RA, Saunders C, Hensel M, and Stamatatos L: N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 2004;78:3279-3295.
25. Kwong PD: Personal communication.
26. Ren X, Sodroski J, and Yang X: An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. J Virol 2005;79:5616-5624.
27. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, and Martin MA: Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol 1998;72:2509-2515.
28. Rivera-Amill V, Noel RJ Jr, Orsini S, et al.: Variable region 4 of SIV envelope correlates with rapid disease progression in morphine-exposed macaques infected with SIV/SHIV. Virology 2007;358:373-383.
29. Michael NL, Chang G, Louie LG, et al.: The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-340.
30. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
31. Frost SD, Liu Y, Pond SL, et al.: Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 2005;79:6523-6527.